ストックスクリーナーアプリを入手
5.61
3.31%
0.18
前日終値:
$5.43
開ける：
$5.44
24時間の取引高:
389.87K
Relative Volume:
1.08
時価総額：
$181.15M
収益：
$4.06M
当期純損益:
$-50.22M
株価収益率:
-3.4662
EPS:
-1.6185
ネットキャッシュフロー:
$-25.37M
1週間 パフォーマンス:
+7.06%
1か月 パフォーマンス:
+12.65%
6か月 パフォーマンス:
+7.57%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$5.25
$5.72
1週間の範囲:
$5.25
$6.25
52週間の値動き範囲:
$2.33
$8.51
Insight Molecular Diagnostics Inc Stock (IMDX) Company Profile
名前
Insight Molecular Diagnostics Inc
セクター
電話
949-409-7600
住所
2 INTERNATIONAL PLAZA DR., SUITE 510, NASHVILLE
Compare IMDX vs TMO, DHR, IDXX, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMDX
Insight Molecular Diagnostics Inc
|
5.61 | 181.15M | 4.06M | -50.22M | -25.37M | -1.6185 |
TMO
Thermo Fisher Scientific Inc
|
469.34 | 174.42B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
180.10 | 127.47B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.88 | 44.24B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
129.84 | 36.67B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
355.53 | 34.91B | 3.77B | 449.25M | 240.68M | 7.8556 |
Insight Molecular Diagnostics Inc Stock (IMDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-28 | 開始されました | Lake Street | Buy |
| 2022-05-24 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-03-14 | ダウングレード | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-01-07 | 開始されました | Stephens | Overweight |
| 2022-01-06 | 再開されました | Piper Sandler | Overweight |
| 2021-03-17 | 再開されました | Needham | Buy |
| 2021-01-07 | アップグレード | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-16 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-11-30 | 開始されました | BTIG Research | Buy |
| 2020-11-10 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2020-07-30 | 繰り返されました | The Benchmark Company | Speculative Buy |
| 2020-07-01 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-06-30 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2020-06-02 | 開始されました | Needham | Buy |
| 2019-02-13 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-29 | アップグレード | Janney | Neutral → Buy |
| 2018-12-19 | 再開されました | Lake Street | Buy |
すべてを表示
Insight Molecular Diagnostics Inc (IMDX) 最新ニュース
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) Stock Price, News & Analysis - Kalkine
Insight Molecular Diagnostics Inc. Announces Publication of GraftAssure CM-Score Demonstrating Superior Performance in Transplant Rejection Monitoring - Quiver Quantitative
IMDX GraftAssure Assay Sets New Standard in Screening - GlobeNewswire
Study: New kidney transplant model doubles reliability of positive results - Stock Titan
iMDx to Highlight In-House Transplant Testing Opportunity and Host Key Opinion Leaders at American Transplant Congress - The Manila Times
iMDx to Highlight In-House Transplant Testing Opportunity - GlobeNewswire
Lake Street Maintains Insight Molecular Diagnostics(IMDX.US) With Buy Rating, Maintains Target Price $12 - Moomoo
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
IMDX Q1 2026 Earnings: Strong EPS Beat Driven by Cost Discipline and Operational EfficiencyEarnings Decline Risk - newsline.com
Insight Molecular Diagnostics (IMDX) Posts Modest Gain; Resistance Test LoomsWave Alternation - newsline.com
IMDX Q1 2026 Earnings: EPS beats estimates by 55% despite revenue absenceFiscal Year Earnings - newsline.com
Insight Molecular Diagnostics Inc. (IMDX) Q1 2026 Earnings: EPS Surprises to the Upside During Pre‑Revenue Phase - The Legal Advocate
Earnings call transcript: Insight Molecular Diagnostics’ Q1 2026 performance and strategic outlook - Investing.com Australia
Insight Molecular Diagnostics Balances Progress and Cash Burn - TipRanks
Insight Molecular Diagnostics Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:IMDX) 2026-05-17 - Seeking Alpha
Lake Street Remains a Buy on Insight Molecular Diagnostics (IMDX) - The Globe and Mail
How Insight Molecular Diagnostics (IMDX) Story Is Shifting With Fresh Capital And GraftAssureDx Submission - Yahoo Finance
BTIG reiterates Neutral on Insight Molecular stock amid FDA review By Investing.com - Investing.com Nigeria
BTIG reiterates Neutral on Insight Molecular stock amid FDA review - Investing.com India
Insight Molecular Q1 2026 Earnings Call Transcript - Sahm
Insight Molecular Diagnostics Inc (IMDX) Q1 2026 Earnings Call H - GuruFocus
IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization - The Manila Times
Insight Molecular Diagnostics (IMDX) Sees Positive Engagement wi - GuruFocus
Insight Molecular Diagnostics expects about $0.25M Q2 2026 revenue while projecting second-quarter cash burn above $9M - MSN
Insight Molecular Diagnostics (IMDX) Q1 2026 Earnings: EPS not d - GuruFocus
Insight Molecular Diagn 1Q Rev $32,000 >IMDX - Moomoo
Insight Molecular Diagnostics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Insight Molecular Diagnostics Q1 2026 sees stock rise 2.41% - Investing.com Australia
IMDX Q1 2026 Earnings Call Transcript - The Globe and Mail
Insight Molecular Diagnostics Inc Q1 Net Income USD -4.29 Million - TradingView
Insight Molecular Diagn 1Q Loss/Shr 12c >IMDX - Moomoo
Insight Molecular Diagnostics : Investor Deck (imdx investor presentation may 2026) - marketscreener.com
Insight Molecular Diagnostics Q1 loss narrows as costs drop - TradingView
Insight Molecular Diagnostics: Q1 Earnings Snapshot - GreenevilleSun.com
Insight Molecular Diagnostics (NASDAQ: IMDX) Q1 2026 revenue collapses to $32K as losses narrow - Stock Titan
Insight Molecular Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[8-K] Insight Molecular Diagnostics Inc. Reports Material Event - Stock Titan
[8-K/A] Insight Molecular Diagnostics Inc. Amends Material Event Report - Stock Titan
Press Release: IMDX Reports Q1 2026 Results and Update on Progress Toward GraftAssure Commercialization - Moomoo
Insight Molecular Diagnostics Inc. Q1 earnings preview - MSN
MSN Money - MSN
IMDX SEC FilingsInsight Molecular Diagnostics Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Insight Molecular Diagnostics Inc expected to post a loss of 26 cents a shareEarnings Preview - TradingView
Number of shareholders of Insight Molecular Diagnostics Inc. – NASDAQ:IMDX - TradingView
Insight Molecular Diagnostics Inc. (IMDX) - Zacks Investment Research
Alpha Buying: Insider Conviction in High-Risk Biotech - Sahm
Insight Molecular Diagnostics Inc (IMDX) 財務データ
収益
当期純利益
現金流量
EPS
0.38%
0.22%
大文字化:
|
ボリューム (24 時間):